Similar articles

• Amphotericin B in visceral leishmaniasis.

  Jha BB. Jha BB. Indian Pediatr. 1996 Nov;33(11):971. Indian Pediatr. 1996. PMID: 9141838 No abstract available.
• Drug watch.

  [No authors listed] [No authors listed] Indian Pediatr. 1998 Jul;35(7):696. Indian Pediatr. 1998. PMID: 10216689 No abstract available.
• Recent advances in the treatment of visceral leishmaniasis.

  Davidson RN, Croft SL. Davidson RN, et al. Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):130-1, 141. doi: 10.1016/0035-9203(93)90457-2. Trans R Soc Trop Med Hyg. 1993. PMID: 8393221 Review. No abstract available.
• Drug combinations for visceral leishmaniasis.

  Olliaro PL. Olliaro PL. Curr Opin Infect Dis. 2010 Dec;23(6):595-602. doi: 10.1097/QCO.0b013e32833fca9d. Curr Opin Infect Dis. 2010. PMID: 20871400 Review.
• Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.

  Kumar D, Ramesh V, Verma S, Ramam M, Salotra P. Kumar D, et al. Ann Trop Med Parasitol. 2009 Dec;103(8):727-30. doi: 10.1179/000349809X12554106963438. Ann Trop Med Parasitol. 2009. PMID: 20030997 No abstract available.